Abstract
Recent data indicates that colorectal cancer treatment outcomes in Poland improved significantly over the last decade. However, substantial regional disparities persist regarding treatment methods, costs, and survival rates. This study analyzes these variations across 16 Polish voivodeships to identify potential systemic inefficiencies.
Introduction
In an ideal healthcare system, a patient’s prognosis should depend on their biology rather than their geographical location. However, "postcode lotteries" remain a challenge in oncology. This research investigates how treatment modalities (surgery, chemotherapy, radiotherapy), costs, and survival outcomes vary across Poland’s regions, aiming to determine if higher spending or specific treatment patterns correlate with better survival.
Methods and Data
The study utilized a retrospective population-based design, drawing from two major sources:
- The National Health Fund (NFZ): Data on 15,281 patients diagnosed with invasive rectal cancer between 2005 and 2007, including detailed treatment and cost information.
- The National Cancer Registry: Historical survival data from 2000–2002 served as a benchmark for progress.
Statistical analyses were performed to find correlations between regional survival rates and variables such as treatment costs, therapy utilization rates, and the ratio of patients to surgical oncology specialists.
Key Findings
Significant Survival Gains
The relative 5-year survival rate for colorectal cancer in Poland rose from 43.7% (2000–2002) to 52.8% (2005–2007). For the rectal cancer subgroup specifically, the survival rate reached 51.6%. Despite this national progress, a gap of 8.4 percentage points exists between the highest and lowest performing regions (ranging from 47.1% to 55.5%).
The Cost-Outcome Paradox
One of the most striking findings was the lack of a statistically significant correlation between the mean cost of treatment in a region and its 5-year survival rate. Some regions with higher expenditures did not see a proportional "survival dividend," suggesting that raw funding is not the primary driver of improved outcomes.
Treatment Modality Variations
Treatment patterns varied widely across the country, often independent of survival outcomes. For instance, radiotherapy utilization ranged from 33.5% to 59.4% depending on the region. This suggests that local hospital culture or infrastructure may dictate treatment paths more than national guidelines.
Specialization and Surgical Trends
A trend ($p = 0.07$) suggested that regions with a lower patient-to-surgical-oncologist ratio tended to have better survival rates, highlighting the potential importance of surgeon specialization. Conversely, the study noted a low rate of hepatic metastasectomy (1.5%), significantly lower than in many Western nations, indicating a need for more specialized hepatobiliary centers.
Discussion and Limitations
While Poland has made strides in cancer care, several limitations in medical informatics at the time of the study must be noted:
- Lack of Staging Data: The NFZ database did not record TNM stages, making it difficult to adjust for disease severity across regions.
- Fixed Costing: NFZ costs are based on fixed procedure rates, which might not capture the true resource intensity of complex cases.
- Recurrence Data: The focus was on overall survival, lacking data on local recurrence—a critical metric for surgical quality.
Conclusion
The significant improvement in rectal cancer survival in Poland is encouraging, yet the persistent regional disparities and the lack of correlation between cost and outcome suggest that optimizing care delivery and specialization may be more impactful than simply increasing funding. Future policy should focus on standardizing care and integrating clinical staging into national health databases to enable more precise performance monitoring.
Summary updated